CR
CRBU.US Caribou Biosciences Inc
- Market cap
- USD 39.1M
- P/E
- -
- P/B
- 0.54x
- ROE
- -132.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is CRBU.US undervalued?
Graham numberThe Graham number of Caribou Biosciences Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Caribou Biosciences Inc fundamental analysis
No fundamental analysis for Caribou Biosciences Inc yet.
Caribou Biosciences Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Caribou Biosciences Inc
Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or ref…
Full company profileCaribou Biosciences Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Caribou Biosciences Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 5.79M | 12.4M | 9.60M | 13.9M | 34.5M | 9.99M | 11.2M | 7.34M |
| Gross Profit | 5.79M | -22.1M | 8.61M | 10.2M | 31.0M | 6.07M | 7.51M | 6.47M |
| Operating Income | -34.3M | -36.1M | -67.0M | -106M | -116M | -167M | -136M | -106M |
| EBITDA | -30.2M | -35.2M | -65.6M | -97.7M | -98.4M | -145M | -145M | -101M |
| Net Income | -23.4M | -34.3M | -66.9M | -99.4M | -102M | -149M | -148M | -101M |
| EPS | -0.85 | -1.24 | -1.11 | -1.64 | -1.38 | -1.65 | -1.59 | -0.94 |
| Balance Sheet | ||||||||
| Total Assets | 61.9M | 36.0M | 442M | 374M | 432M | 313M | 175M | 123M |
| Total Liabilities | 54.5M | 59.5M | 54.5M | 72.9M | 63.8M | 60.4M | 53.2M | 46.4M |
| Shareholders' Equity | 7.46M | -23.4M | 388M | 301M | 368M | 253M | 122M | 76.6M |
| Cash & Short-term Investments | 49.5M | 16.0M | 376M | 248M | 329M | 210M | 139M | 94.8M |
| Total Debt | 532K | 1.58M | 259K | 27.7M | 27.1M | 26.5M | 27.2M | 26.3M |
| Cash Flow | ||||||||
| Operating Cash Flow | -32.0M | -33.2M | -32.5M | -91.0M | -93.3M | -138M | -111M | -96.4M |
| Capital Expenditure | 884K | 1.32M | 3.12M | 7.05M | 11.6M | 6.51M | 1.36M | 123K |
| Free Cash Flow | -32.9M | -34.5M | -35.6M | -98.0M | -105M | -145M | -112M | -96.5M |
| Ratios | ||||||||
| ROE | -314.0% | - | -17.3% | -33.0% | -27.7% | -58.9% | -121.2% | -132.2% |
| ROA | -37.8% | -95.2% | -15.1% | -26.6% | -23.6% | -47.6% | -84.5% | -82.3% |
| Net Profit Margin | -404.8% | -277.6% | -697.3% | -717.8% | -296.1% | -1,491.9% | -1,327.4% | -1,380.7% |
| Debt to Equity | 0.07x | - | 0.00x | 0.09x | 0.07x | 0.10x | 0.22x | 0.34x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Caribou Biosciences Inc dividends
Caribou Biosciences Inc has not paid dividends in the last 7 fiscal years.
Who owns Caribou Biosciences Inc
- Insiders 8.81%
- Institutions 46.14%
- Public & others 45.06%
- Shares outstanding 108M
- Free float 104M
Top funds holding CRBU.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 3.01M | 2.79% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 2.24M | 2.08% | 0.00% | Oct 2026 |
| ACATIS Datini Valueflex Fonds A | 2.00M | 1.85% | 0.00% | Sep 2026 |
| Canada Life US Small-Mid Cap Growth F | 1.44M | 1.34% | 0.00% | Aug 2026 |
| Selectra J. Lamarck Biotech A | 1.43M | 1.32% | 0.00% | Oct 2026 |
| Fidelity Small Cap Index | 997K | 0.92% | 0.00% | Aug 2026 |
| iShares Russell 2000 Value ETF | 880K | 0.81% | 0.00% | Oct 2026 |
| iShares Biotechnology ETF | 694K | 0.64% | -0.19% | Oct 2026 |
| Schwab US Small-Cap ETF™ | 573K | 0.53% | +0.24% | Oct 2026 |
| Vanguard Russell 2000 ETF | 531K | 0.49% | +0.64% | Sep 2026 |
| Fidelity Extended Market Index | 500K | 0.46% | +11.88% | Sep 2026 |
| Mackenzie GQE US Small Cap F8 | 467K | 0.43% | 0.00% | Aug 2026 |
| Fidelity Enhanced Small Cap Core ETF | 348K | 0.32% | +0.27% | Oct 2026 |
| Galileo - Biotech Innovation Fund S USD | 300K | 0.28% | 0.00% | Apr 2026 |
| IG Mackenzie GQE U.S. Sm Md Cap Eq C NL | 295K | 0.27% | 0.00% | Jul 2026 |
| iShares Micro-Cap ETF | 276K | 0.26% | 0.00% | Oct 2026 |
| Dimensional US Small Cap ETF | 255K | 0.24% | 0.00% | Oct 2026 |
| Bruce | 250K | 0.23% | 0.00% | Sep 2026 |
| Schwab Small Cap Index | 224K | 0.21% | 0.00% | Sep 2026 |
| AXS Green Alpha ETF | 212K | 0.20% | 0.00% | Oct 2026 |
Top institutions holding CRBU.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 7.82M | 7.23% | +264.70% | Jun 2026 |
| Pfizer Inc | 4.69M | 4.34% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 4.21M | 3.90% | +11.72% | Jun 2026 |
| Mackenzie Investments | 3.65M | 3.38% | +287.23% | Jun 2026 |
| Renaissance Technologies Corp | 2.77M | 2.57% | +7.07% | Jun 2026 |
| Kynam Capital Management, LP | 2.50M | 2.32% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 2.37M | 2.20% | +133.30% | Jun 2026 |
| Acadian Asset Management LLC | 1.77M | 1.64% | +91.83% | Jun 2026 |
| State Street Corp | 1.63M | 1.51% | +285.79% | Jun 2026 |
| Bank of America Corp | 1.41M | 1.31% | +8.77% | Jun 2026 |
| Two Sigma Investments LLC | 1.05M | 0.97% | -40.55% | Jun 2026 |
| Charles Schwab Investment Management Inc | 776K | 0.72% | +38.63% | Jun 2026 |
| CAMBRIDGE Invest RESEARCH ADVISORS, INC. | 765K | 0.71% | +39.82% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 749K | 0.69% | -23.23% | Sep 2026 |
| FMR Inc | 727K | 0.67% | +0.44% | Jun 2026 |
| Northern Trust Corp | 713K | 0.66% | +227.45% | Jun 2026 |
| Maverick Capital Ltd | 653K | 0.60% | 0.00% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 614K | 0.57% | 0.00% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 606K | 0.56% | +16.59% | Jun 2026 |
| Green Alpha Advisors, LLC | 551K | 0.51% | +51.36% | Sep 2026 |
Caribou Biosciences Inc company profile
- Company name
- Caribou Biosciences Inc
- Ticker
- CRBU.US
- Exchange
- USA Stocks
- Listed since
- Jul 23, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 97
- Fiscal year end
- December
- Address
- 2929 7th Street, Berkeley, CA, United States, 94710
- Phone
- 510 982 6030
- Website
- cariboubio.com
About Caribou Biosciences Inc
Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
Caribou Biosciences Inc management
9- Dr. Rachel E. Haurwitz Ph.D.Co-Founder, CEO, President & Director · born 1986
- Mr. Sriram Ryali M.B.A.Chief Financial Officer · born 1982
- Ms. Barbara G. McClung Esq., J.D.Chief Legal Officer & Corporate Secretary · born 1955
- Dr. Jennifer A. Doudna Ph.D.Co-founder & Member of Scientific Advisory Board · born 1964
- Mr. Ryan FischesserInterim Principal Accounting Officer & Controller
- Dr. Justin Skoble Ph.D.Senior Vice President of Technical Operations
- Ms. Reigin ZawadzkiChief People Officer
- Dr. Tina Albertson M.D., Ph.D.Chief Medical Officer · born 1974
- Mr. Enrique Zudaire Ph.D.Senior Vice President of Translational Research